# US 2013/0157888 A1 · Diagnostic autoantibody profiles for the detection and diagnosis of neurodegenerative diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0157888 A1
- Document ID: US20130157888A1
- Status: Published application
- Kind: A1
- Application number: 13/697,601
- Filed: 2011-04-01
- Published: 2013-06-20
- Earliest claimed: 2010-05-13
- Assignees: University of Medicine and Dentistry of New Jersey
- Inventors: Robert G. Nagele
- Web page: https://patentgrep.com/patent/US20130157888A1

## CPC

- G01N 33/6854: {Immunoglobulins}
- G01N 33/564: for pre-existing immune complex or autoimmune disease {, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9}
- G01N 33/6896: {Neurological disorders, e.g. Alzheimer's disease}
- G01N 2800/2821: Alzheimer
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention provides methods, compositions, and kits for the detection of neurodegenerative disease specific autoantibodies for the diagnosis of neurodegenerative diseases and risk for developing neurodegenerative diseases, and for the generation of patient-specific neurodegenerative disease diagnostic autoantibody profiles.

## Claims

### Claim 1

A method for detecting neurodegenerative disease diagnostic autoantibodies in a subject comprising:
(a) obtaining an immunoglobulin-containing biological sample from the subject, and
(b) performing an assay to determine the presence or absence of one or more neurodegenerative disease diagnostic autoantibodies in the biological sample.

### Claim 2

A method for diagnosing a neurodegenerative disease in a subject comprising:
(a) obtaining an immunoglobulin-containing biological sample from the subject,
(b) performing an assay to determine the presence or absence of one or more neurodegenerative disease diagnostic autoantibodies in the biological sample, and
(c) diagnosing said neurodegenerative disease if one or more of the disease diagnostic autoantibodies is present.

### Claim 3

A method for identifying a subject at risk for developing a neurodegenerative disease comprising:
(a) obtaining an immunoglobulin-containing biological sample from the subject,
(b) performing an assay to determine the presence or absence of one or more neurodegenerative disease diagnostic autoantibodies in the biological sample, and
(c) identifying the subject as at risk for said neurodegenerative disease if one or more of the disease diagnostic autoantibodies is present.

### Claim 4

A method of generating a subject-specific, neurodegenerative disease-specific autoantibody profile comprising:
(a) obtaining an immunoglobulin-containing biological sample from a subject,
(b) performing an assay to determine the presence or absence of one or more neurodegenerative disease diagnostic autoantibodies in the biological sample, and
(c) generating a subject-specific neurodegenerative disease-specific autoantibody profile of the disease diagnostic autoantibodies present in the sample.

### Claim 5 (depends on 1)

The method of claim 1, wherein said neurodegenerative disease is selected from the group consisting of Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, multiple sclerosis. Guillain-Barre syndrome, chronic peripheral neuropathy, optic neuritis, vascular dementia, obsessive compulsive disorder, Sydenham's chorea, PANDAS, Hashimoto's encephalopathy, schizophrenia, systemic lupus erythematosus, vascular cognitive disorders, stroke, Huntington's disease, neuromyelitis optica, paraneoplastic syndromes, limbic encephalitis, Rasmussen encephalitis, Hashimoto's encephalitis, encephalitis lethargica, stiff person syndrome, post-streptococcal movement disorders, rheumatic fever, gluten enteropathy, ASD, autism, dyslexia, HTLV-1-associated myelopathy/tropical spastic paraparesis, myasthenia gravis, Lambert-Eaton syndrome, and arthrogryposis multiplex congenita

### Claim 6 (depends on 1)

The method of claim 1, wherein said subject is a human.

### Claim 7 (depends on 1)

The method of claim 1, wherein said biological sample is selected from the group consisting of whole blood, serum, cerebrospinal fluid, saliva, and sputum.

### Claim 8 (depends on 1)

The method of claim 1, or wherein said assay is performed by contacting the sample with one or more autoantigens that are specific for a disease-specific autoantibody under conditions that allow an immunocomplex of the autoantigen and the autoantibody to form, and detecting the presence or absence of an immunocomplex, wherein the presence of an immunocomplex is indicative of the presence of a neurodegenerative disease-specific autoantibody and wherein the absence of an immunocomplex is indicative of the absence of a neurodegenerative disease-specific autoantibody.

### Claim 9 (depends on 8)

The method of claim 8 wherein the one or more autoantigens are attached to a substrate.

### Claim 10 (depends on 8)

The method of claim 8 wherein the one or more antigens are in the form of an array.

### Claim 11 (depends on 10)

The method of claim 10 wherein the array is a microarray.

### Claim 12 (depends on 9)

The method of claim 9 wherein the substrate is a nitrocellulose-coated glass slide.

### Claim 13

A substrate on which one or more autoantigens that are specific for a neurodegenerative disease-specific autoantibody are immobilized.

### Claim 14 (depends on 13)

The substrate of claim 13 having immobilized thereon a plurality of individually addressable autoantigens that are specific for neurodegenerative disease diagnostic autoantibodies.

### Claim 15 (depends on 13)

The substrate of claim 13 comprising a plurality of panels of autoantigens wherein each panel contains autoantigens that are diagnostic for one neurodegenerative disease.

### Claim 16 (depends on 13)

The substrate of claim 13 wherein the substrate is a slide or a bead.

### Claim 17

A microarray comprising a substrate on which one or more autoantigens that are specific for a neurodegenerative disease-specific autoantibody are immobilized.

### Claim 18 (depends on 17)

The microarray of claim 17 comprising a plurality of panels of autoantigens wherein each panel contains autoantigens that are diagnostic for one neurodegenerative disease.

### Claim 19

A kit comprising one or more autoantigens that are specific for a neurodegenerative disease-specific autoantibody and means for determining binding of the autoantigen to an antibody in an immunoglobulin-containing biological sample.

### Claim 20 (depends on 19)

The kit of claim 19 wherein the one or more autoantigens are immobilized on a substrate.
